Cambrex Reports Fourth Quarter and Full Year 2017 Financial Results

- February 8th, 2018

Cambrex (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: Net revenue increased 2.5% to $182.3 million compared to $177.9 million in the same quarter last year.  Excluding the impact of foreign … Continued

Cambrex (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

Net revenue increased 2.5% to $182.3 million compared to $177.9 million in the same quarter last year.  Excluding the impact of foreign exchange, net revenue increased 1%. Full year net revenue increased 9% to $534.5 million, compared to $490.6 million in the full year 2016.

Click here to read the full press release.

The newest developments in genetics investing

 
Find out what to watch for in the world of genetics

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply